NasdaqGS:ZYMEBiotechs
A Look At Zymeworks (ZYME) Valuation After Recent Clinical And Regulatory Milestones
Zymeworks (ZYME) stock has been reacting to a series of clinical and regulatory milestones, including new Phase 1 data, a U.S. PDUFA date, and a China filing for its HER2 targeted therapy.
See our latest analysis for Zymeworks.
Despite the recent clinical and regulatory progress, Zymeworks shares have come under pressure in the short term, with the 1 month share price return down 12.93% and the year to date share price return down 9.69%. However, the 1 year total shareholder return of 90.79%...